

1P-814-T025

Monoclonal Antibody to CD138 Phycoerythrin (PE) conjugated (25 tests)

Clone:	MI15
lsotype:	Mouse IgG1
Specificity:	The mouse monoclonal antibody MI15 recognizes CD138 (syndecan 1), a 65-70 kDa heparan sulfate proteoglycan expressed mainly in the epidermis and plasma cells, but also in growth factor-stimulated lymphocytes.
Regulatory Status:	RUO
Immunogen:	A mixture of U266 and XG-1 human myeloma cell lines
Species Reactivity:	Human, Non-Human Primates, Rat
Preparation:	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μ I reagent / 100 μ I of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.25 mI) is sufficient for 25 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD138 (syndecan 1) is a transmembrane proteoglycan that can bind a variety of cytokines and modulate their activity, as well as the activity of extracellular matrix components and influence many developmental processes. CD138 is expressed mainly in differentiating keratinocytes and is transiently upregulated in all layers of the epidermis upon tissue injury. It is also highly expressed on plasma cells and can be detected even on fibroblasts, vascular smooth muscle cells and endothelial cells. Up-regulation and down-regulation of CD138 on the cell surface often correlates with the gain of cancerous characteristics. Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis.

For laboratory research only, not for drug, diagnostic or other use.



References:

*Gattei V, Godeas C, Degan M, Rossi FM, Aldinucci D, Pinto A: Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. Br J Haematol. 1999 Jan;104(1):152-62.

*Krishnan SR, Luk F, Brown RD, Suen H, Kwan Y, Bebawy M: Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma. Neoplasia. 2016 Jan;18(1):25-32.

*Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N: Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst. 2012 Jul 3;104(13):1005-20.

*Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, Zannettino AC: PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol. 2015 Oct 6;8:106.

*Nadalin MR, Fregnani ER, Silva-Sousa YT, Perez DE: Syndecan-1 (CD138) and Ki-67 expression in odontogenic cystic lesions. Braz Dent J. 2011;22(3):223-9.

*Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Rème T, Bolloré K, Vendrell JP, Le Gallou S, Mourcin F, De Vos J, Kassambara A, Duperray C, Hose D, Fest T, Tarte K, Klein B: Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011 Oct 15;187(8):3931-41.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.